Company Profile
Travere Therapeutics Stock Price, News & Catalysts
- Ticker:
- TVTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
65.22 USD (-0.75%)
Close
Last updated: August 24, 2026
3.99B USD
Market cap
Why the stock is moving
As of Aug 24, 2026, TVTX closed down 0.75% at $65.22. No new same-company headline was identified in the current news window.
Company overview
Business overview
Travere Therapeutics is a rare-disease company with a focus on kidney and hepatology programs. Its business combines commercial execution with pipeline development in hard-to-treat diseases.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Travere sits in specialty biopharma.
Business Model Characteristics
The model is driven by product adoption, label expansion, and development in additional rare disease settings.
Position Within the Biotechnology Landscape
Travere is a specialty-rare-disease name whose stock can move on both commercial traction and pipeline progress.
Future catalysts
- Travere's catalysts are FILSPARI execution in IgA nephropathy and any FSGS or label-expansion step that widens the renal franchise. The company improves when the nephrology story keeps compounding.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Travere Therapeutics (TVTX)?
Travere Therapeutics (TVTX) most recently closed at 65.22 USD, a -0.75% move versus the previous session.
What is the market cap of Travere Therapeutics (TVTX)?
Travere Therapeutics currently has a market capitalization of 3.99B USD on BioPharmSignal.
What does Travere Therapeutics do?
Travere Therapeutics is a rare-disease company with a focus on kidney and hepatology programs. Its business combines commercial execution with pipeline development in hard-to-treat diseases.
On which exchange is TVTX stock listed?
Travere Therapeutics (TVTX) is associated with NASDAQ, United States, Biopharma.
What is Travere?
Travere's catalysts are FILSPARI execution in IgA nephropathy and any FSGS or label-expansion step that widens the renal franchise.
Which conditions is Travere Therapeutics targeting with Travere?
Travere's catalysts are FILSPARI execution in IgA nephropathy and any FSGS or label-expansion step that widens the renal franchise.
How does Travere Therapeutics describe recent progress with Travere?
Travere's catalysts are FILSPARI execution in IgA nephropathy and any FSGS or label-expansion step that widens the renal franchise.
What is Therapeutics?
Travere Therapeutics is a rare-disease company with a focus on kidney and hepatology programs.